분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-02-24 03:47:12 , Hit : 1309
 CRISPR Turbocharges CAR T Cells, Boosts Cancer Immunotherapy

GEN News Highlights
More »
February 23, 2017

http://www.genengnews.com/gen-news-highlights/crispr-turbocharges-car-t-cells-boosts-cancer-immunotherapy/81253925?utm_medium=newsletter&utm_source=GEN+Daily+News+Highlights&utm_content=01&utm_campaign=GEN+Daily+News+Highlights_20170223


In a model of acute lymphoblastic leukemia, CAR T cells created with CRISPR outperformed those made with technology that relies on randomly integrating vectors.

When T cells are modified to fight cancer more effectively, cellular mechanics don’t pick up a socket wrench. Instead, they take hold of retroviral or lentiviral technology, which is used to install genes for synthetic T-cell receptors. Such technology, however, doesn’t always place genes in just the right place. Enter Mr. GoodCRISPR. This mechanic uses CRISPR gene-editing technology, which is more precise.

CRISPR can be used to install genes, such as chimeric antigen receptor (CAR) genes, into specific parts of the genome. Presumably, when CRISPR is used to build CAR T cells, their genomic engines will run more smoothly—and rack up more trouble-free miles. Such endurance is important for CAR T cells, which are being used in immunotherapy applications. These are long-distance races, and they are particularly grueling when CAR T cells must outpace cancer.

A road test of sorts has been staged by scientists based at Memorial Sloan Kettering Cancer Center (MSK). They decided that CRISPR T-cell engineering might be more effective than conventional T-cell engineering, which, the scientists have observed, can result in clonal expansion, oncogenic transformation, variegated transgene expression, and transcriptional silencing.

The scientists built CRISPR-engineered CAR T cells and evaluated their efficacy in a model of acute lymphoblastic leukemia. The results of this work appeared February 22 in Nature, in an article entitled, “Targeting a CAR to the TRAC Locus with CRISPR/Cas9 Enhances Tumour Rejection.” As the title suggests, the MSK team took advantage of CRISPR’s ability to deliver genes to selected genomic loci.

“Here we show that directing a CD19-specific CAR to the T-cell receptor α constant (TRAC) locus not only results in uniform CAR expression in human peripheral blood T cells, but also enhances T-cell potency, with edited cells vastly outperforming conventionally generated CAR T cells in a mouse model of acute lymphoblastic leukaemia,” wrote the article’s authors. “We further demonstrate that targeting the CAR to the TRAC locus averts tonic CAR signalling and establishes effective internalization and re-expression of the CAR following single or repeated exposure to antigen, delaying effector T-cell differentiation and exhaustion.”

Essentially, the MSK team showed that CRISPR technology can deliver a CAR gene to a very specific location in the genome of the T cell. Moreover, the team demonstrated that this precise approach resulted in CAR T cells that had more stamina.

The CRISPR-modified T cells are able to kill tumor cells for longer because they are less prone to exhaustion. More robust T cells could eventually lead to safer, more effective use of cell-based immunotherapy in patients.

"Cancer cells are relentless in their attempt to evade treatment, so we need CAR T cells that can match and outlast them," explained Michel Sadelain, M.D., Ph.D., senior author on the Nature paper and director of the Center for Cell Engineering and the Gene Transfer and Gene Expression Laboratory at MSK. "This new discovery shows that we may be able to harness the power of genome editing to give these 'living therapies' a built-in boost. We are eager to continue exploring how genome-editing technology could give us the next generation of CAR T cell therapy."

Some of the first clinical trials using CRISPR technology are currently in the planning stages. Dr. Sadelain and his team aim to eventually explore the safety and efficacy of these CRISPR-built CAR T cells in a trial.







1027   아수라장 속에서 탄생한 생명  이성욱 2014/12/17 1250
1026   유전자 넉아웃을 보상하는 또 다른 유전자  이성욱 2015/07/30 1253
1025   CRISPR-Cas9 Inhibitors Found in Metagenomics Study  이성욱 2019/02/07 1254
1024   역풍 맞은 사이언스 논문 - 암은 대부분 운이 나빠 발생한다?  이성욱 2015/01/21 1255
1023   생물안전 규제를 우회하는 유전체교정 기법: 외부 DNA 없는 CRISPR  이성욱 2015/10/21 1270
1022   세균이 위협을 기억하는데 도움을 주는 바이러스 절단 효소  이성욱 2015/02/25 1275
1021   Genzyme, Voyager Launch Up-to-$845M Gene Therapy Collaboration  이성욱 2015/02/14 1277
1020   환기불량이 한국에서 MERS 슈퍼전파를 일으켰을까?  이성욱 2015/06/09 1279
1019   술의 역사: 영장류가 진화한 것은 알코올 섭취능력 때문?  이성욱 2014/12/04 1285
1018   에볼라에 대한 반응과 유전적 요인  이성욱 2014/11/04 1289
1017   EMA panel recommends approval of DAA regimen for patients with HCV  이성욱 2014/11/26 1292
1016   Novartis Extends Deal to Use SomaLogic Proteomics Technology  이성욱 2014/10/23 1296
1015   남성 동성애와 관련된 후성유전학 태그  이성욱 2015/10/12 1302
1014   암확산을 중단시키는 박테리아 소통시스템  이성욱 2014/09/29 1305
1013   Roche says to buy Danish Santaris for up to $450 million  이성욱 2014/08/06 1308
  CRISPR Turbocharges CAR T Cells, Boosts Cancer Immunotherapy  이성욱 2017/02/24 1309
1011   STAP세포논문철회에서 새롭게 밝혀진 사실들  이성욱 2014/09/15 1311
1010   CVS Gives Preferred Status to Gilead’s Hepatitis C Drugs  이성욱 2015/01/07 1312
1009   단일 돌연변이가 망막 종양으로 이어지는 이유  이성욱 2014/09/29 1328
1008   Genetically 'edited' fruit could soon hit supermarket shelves  이성욱 2014/08/15 1331

[이전 10개] [1]..[11][12] 13 [14][15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2022 Zeroboard / skin by ROBIN